## Faculty

### **Chairman:**

**Dr Alexander T. Cohen** King's College Hospital London, UK

### **Expert Panel:**

**Dr Alexander T. Cohen** King's College Hospital London, UK

**Professor Sylvia Haas** Technical University of Munich Munich, Germany

Dr Marcel Levi

University of Amsterdam Amsterdam, the Netherlands

#### Real-time participation and virtual attendance

#### Connecting to the virtual platform via PC or Mac:

- We recommend that you test your system at: www.test.ps-vevent.com to ensure your laptop is configured appropriately
- 2. Using a browser that supports Flash Player, go to: www.bayer-eahp.com
- 3. Enter your email address, first name, last name, country and speciality then click 'Join'

## Connecting via iPad, iPhone, iPod Touch or Android device:

- Connect to our virtual platform using the free Adobe<sup>®</sup> Connect<sup>™</sup> Mobile app available from:
  - iTunes Store: www.itunes.ps-vevent.com
- Google Play: www.google-play.ps-vevent.com
- 2. To join the symposium, in your mobile browser go to: www.bayer-eahp.com or scan the QR code below
- 3. Enter your email address, first name, last name, country and speciality then click 'Join'

Once logged-in, you can view the slides, participate in polls and submit questions to the Expert Panel

If you experience any problems, please contact vevent@photosound.com



#### Sponsored by Bayer HealthCare Pharmaceuticals

In the EU, rivaroxaban is marketed under the trade name Xarelto<sup>®</sup>. Marketing authorization may vary from country to country. In France, rivaroxaban is approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors for stroke, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

G.GM.XA.02.2013.0173 BHP/100319/0313

© Bayer HealthCare Pharmaceuticals 2013



150 Years Science For A Better Life

# Treating and Preventing Blood Clots... ...Practical Considerations with Rivaroxaban

Chaired by Alexander T. Cohen

## Wednesday 13 March 2013, 14:00–15:30

Amphi Bordeaux, Level 3 Le Palais des Congrès de Paris Paris, France

A Satellite Symposium sponsored by Bayer HealthCare Pharmaceuticals at the 18th Congress of the European Association of Hospital Pharmacists Paris, France 13–15 March 2013

## Enhance your symposium experience

Our virtual platform will help both in-room and remote attendees get the most out of this symposium

**In the room?** Participate in polls and ask questions to the panel via the virtual platform

Unable to attend? Why not join the symposium virtually?

Please see the back page for instructions on how to join



150 Years Science For A Better Life



## **Chairman's Welcome**

#### Dear Colleagues,

I am delighted to invite you to attend this Satellite Symposium at the 18th Congress of the European Association of Hospital Pharmacists, entitled 'Treating and Preventing Blood Clots...Practical Considerations with Rivaroxaban'. This symposium will provide an opportunity to share knowledge and experience in the use of rivaroxaban across multiple indications.

Rivaroxaban has transformed the management of thromboembolic disease, and clinical experience with the use of rivaroxaban in multiple indications is growing rapidly. An understanding of the practical management of rivaroxaban is essential in order to optimize patient outcomes and ensure cost-effectiveness within healthcare systems. During this interactive symposium, the Expert Panel will summarize key findings from the extensive rivaroxaban clinical trial programme and highlight the breadth of indications and the benefits offered by rivaroxaban to real-world practice. Data elucidating the burden of thromboembolic disease and examining the use of rivaroxaban as a cost-effective approach will be presented. Thereafter, the optimal management of patients receiving rivaroxaban therapy and practical approaches to ensuring both safety and compliance will be explored.

The Expert Panel will then answer your questions related to the practical management of rivaroxaban, as well as discuss their experiences of using rivaroxaban in daily clinical practice.

I hope that you will be able to join us for what promises to be a very engaging, interactive and informative symposium.

Kind regards,

Alexander T. Cohen

## Programme

Chaired by Alexander T. Cohen Wednesday 13 March 2013, 14:00-15:30 Amphi Bordeaux, Level 3, Le Palais des Congrès de Paris, Paris, France

- Welcome and introduction 14:00 Alexander T. Cohen, UK
- Breadth of indication matters... 14:05 One drug for multiple indications Sylvia Haas, Germany
- 14:25 Cost matters...Cost-effective management of thromboembolic disease Alexander T. Cohen, UK
- Experience matters... 14:45 Practical management in your hospital Marcel Levi, the Netherlands
- 15:05 Interactive O&A session Expert Panel chaired by Alexander T. Cohen, UK
- 15:25 Summary and close Alexander T. Cohen, UK

"Don't forget to join the symposium online to view the slides, take part in polls and ask questions to the panel. See the back page for instructions"